Cargando…

Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients

SIMPLE SUMMARY: Melanoma has become the most rapidly increasing cancer in Caucasian populations, causing 90% of skin cancer mortality. FDG-PET/CT has been recommended by the European 2019 guidelines for melanoma for staging and treatment response assessment in advanced melanoma highlighting the need...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kudura, Ken, Dimitriou, Florentia, Basler, Lucas, Förster, Robert, Mihic-Probst, Daniela, Kutzker, Tim, Dummer, Reinhard, Mangana, Joanna, Burger, Irene A., Kreissl, Michael C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345158/ https://www.ncbi.nlm.nih.gov/pubmed/34359730 http://dx.doi.org/10.3390/cancers13153830

Ejemplares similares

Correction: Kudura et al. Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients. Cancers 2021, 13, 3830
por: Kudura, Ken, et al.
Publicado: (2022)

Malignancy Rate of Indeterminate Findings on FDG-PET/CT in Cutaneous Melanoma Patients
por: Kudura, Ken, et al.
Publicado: (2021)

Improved detection of in-transit metastases of malignant melanoma with BSREM reconstruction in digital [(18)F]FDG PET/CT
por: Liberini, Virginia, et al.
Publicado: (2021)

Predictive Value of Baseline FDG-PET/CT for the Durable Response to Immune Checkpoint Inhibition in NSCLC Patients Using the Morphological and Metabolic Features of Primary Tumors
por: Kudura, Ken, et al.
Publicado: (2022)

Frequency, Treatment and Outcome of Immune-Related Toxicities in Patients with Immune-Checkpoint Inhibitors for Advanced Melanoma: Results from an Institutional Database Analysis
por: Dimitriou, Florentia, et al.
Publicado: (2021)

Hair Depigmentation and Hair Loss in Advanced Melanoma Treated with Combined Immunotherapy and Targeted Therapy
por: DIMITRIOU, Florentia, et al.
Publicado: (2020)

PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors
por: Gabryś, H. S., et al.
Publicado: (2022)

Additional Primary Tumors Detected Incidentally on FDG PET/CT at Staging in Patients with First Diagnosis of NSCLC: Frequency, Impact on Patient Management and Survival
por: Kudura, Ken, et al.
Publicado: (2023)

An Innovative Non-Linear Prediction Model for Clinical Benefit in Women with Newly Diagnosed Breast Cancer Using Baseline FDG-PET/CT and Clinical Data
por: Kudura, Ken, et al.
Publicado: (2023)

Triple Combination of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in BRAFV600 Melanoma: Current Status and Future Perspectives
por: Welti, Michèle, et al.
Publicado: (2022)

Sex-Related Differences in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibition
por: Kudura, Ken, et al.
Publicado: (2022)

Inflammatory Blood Parameters as Biomarkers for Response to Immune Checkpoint Inhibition in Metastatic Melanoma Patients
por: Kudura, Ken, et al.
Publicado: (2022)

Melanoma patients with additional primary cancers: a single-center retrospective analysis
por: Dimitriou, Florentia, et al.
Publicado: (2019)

Predictive Value of Total Metabolic Tumor Burden Prior to Treatment in NSCLC Patients Treated with Immune Checkpoint Inhibition
por: Kudura, Ken, et al.
Publicado: (2023)

Sarcoid-like reactions in patients receiving modern melanoma treatment
por: Dimitriou, Florentia, et al.
Publicado: (2018)

Long-term pegylated interferon-α and its potential in the treatment of melanoma
por: Dummer, Reinhard, et al.
Publicado: (2009)

Expression of MAGE-C1/CT7 and MAGE-C2/CT10 Predicts Lymph Node Metastasis in Melanoma Patients
por: Curioni-Fontecedro, Alessandra, et al.
Publicado: (2011)

A new B-Raf inhibitor combo for advanced melanoma
por: Barysch, Marjam-Jeanette, et al.
Publicado: (2018)

Value of troponin T versus I in the diagnosis of immune checkpoint inhibitor‐related myocarditis and myositis: rechallenge?
por: Rossi, Valentina A., et al.
Publicado: (2023)

Whole-body parametric [(18)F]-FDG PET/CT improves interpretation of a distant lesion as venous embolus in a lung cancer patient
por: Messerli, Michael, et al.
Publicado: (2021)

Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET/CT in patients with melanoma
por: Amrane, Karim, et al.
Publicado: (2019)

Hypermetabolic Ipsilateral Supraclavicular and Axillary Lymphadenopathy: Optimal Time Point for Performing an (18)F-FDG PET/CT after COVID-19 Vaccination
por: Antwi, Kwadwo, et al.
Publicado: (2022)

(18)F-FDG PET-CT for Staging of Conjunctival Melanoma
por: Damian, Andres, et al.
Publicado: (2013)

Intratumoral Heterogeneity of MAGE-C1/CT7 and MAGE-C2/CT10 Expression in Mucosal Melanoma
por: Curioni-Fontecedro, A., et al.
Publicado: (2015)

(18)F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma
por: Wong, Annie, et al.
Publicado: (2020)

Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [(18)F]FDG PET/CT in Metastatic Melanomas and Lung Cancer
por: Lopci, Egesta
Publicado: (2021)

Erratum to “Intratumoral Heterogeneity of MAGE-C1/CT7 and MAGE-C2/CT10 Expression in Mucosal Melanoma”
por: Curioni-Fontecedro, A., et al.
Publicado: (2019)

Colonic Malignant Melanoma: (18)F-FDG PET/CT Findings
por: Kaya, Eser, et al.
Publicado: (2018)

Predictive value and accuracy of [(18)F]FDG PET/CT modified response criteria for checkpoint immunotherapy in patients with advanced melanoma
por: Ayati, Narjess, et al.
Publicado: (2023)

Myocardial (18)F-FDG Uptake Pattern for Cardiovascular Risk Stratification in Patients Undergoing Oncologic PET/CT
por: Haider, Ahmed, et al.
Publicado: (2020)

Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma
por: Ferdinandus, Justin, et al.
Publicado: (2022)

Tumor Cell Plasticity and Angiogenesis in Human Melanomas
por: Mihic-Probst, Daniela, et al.
Publicado: (2012)

Appearance of CNS histoplasmosis on (18)F-FDG PET/CT with MRI correlation
por: Makis, William, et al.
Publicado: (2016)

Diffuse Cutaneous Melanosis Associated with Malignant Melanoma
por: Mangana, Joanna, et al.
Publicado: (2015)

How I treat metastatic melanoma
por: Dummer, Reinhard, et al.
Publicado: (2019)

Can Dynamic Whole-Body FDG PET Imaging Differentiate between Malignant and Inflammatory Lesions?
por: Skawran, Stephan, et al.
Publicado: (2022)

FDG-PET/CT in lymphoma
por: D'souza, Maria M, et al.
Publicado: (2013)

[(18)F]FDG PET/CT in the Evaluation of Melanoma Patients Treated with Immunotherapy
por: Mangas Losada, María, et al.
Publicado: (2023)

Cardiac Metastasis of Malignant Melanoma Detected by (18)F-FDG PET/CT
por: Zhang, Hongzhe, et al.
Publicado: (2023)

FDG-PET and PET/CT - Part II
por: Takalkar, Amol M, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_4m60kmgefutjtkbtttr6e3ia1h